Germline HLA-I genotypes predict pathologic response and survival outcomes in esophageal cancer patients undergoing neoadjuvant immunochemotherapy: a retrospective cohort study.

Abstract excerpt

BACKGROUND: Neoadjuvant immunochemotherapy (nICT) has reshaped the treatment paradigm for locally advanced esophageal cancer (EC), but patient responses remain highly heterogeneous. Reliable biomarkers to predict therapeutic benefit are urgently needed. Class I human leukocyte antigen (HLA-I) molecules are essential for anti-tumor immunity, presenting neoantigens to cytotoxic T lymphocytes.This study investigated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Combined Chemotherapy Protocols
• Share to Biomarkers, Tumor